NCT03564054终止不适用
Multi-Center, Randomized Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Treatment time until failure
研究概览
简要总结
The purpose of the study is to assess the efficacy of photodynamic therapy (PDT) in relieving airway obstruction in subjects with lung cancer compared to treatment with argon plasma coagulation (APC).
详细描述
This is a multi-center, randomized study that will compare the efficacy of photodynamic therapy (PDT) and argon plasma coagulation (APC) in the treatment of airway obstruction caused by non small cell lung cancer. Participants will be randomized in a 1:1 ratio to receive treatment with one of these two treatment modalities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures.
- •Subjects must have a biopsy proven for non-small cell lung cancer with obstructing or partially obstructing endobronchial tumor involving the main stem bronchus or bronchus intermedius, or lobar bronchus with or without extrabronchial tumor.
- •Both males and females ≥ eighteen years of age
- •Subject must demonstrate at least a 50% airway stenosis due to endobronchial tumor.
- •Subject must demonstrate symptoms of cough, hemoptysis, dyspnea etc. attributable to partially or completely occluding endobronchial tumor.
- •Subject is able to tolerate multiple bronchoscopies.
- •Subjects who were previously treated with chemotherapy or radiotherapy are eligible for study entry. Such subjects must be at least 2 weeks post-radiotherapy and must have recovered from all acute toxicities associated with such treatment.
- •A predicted life expectancy of at least 90 days.
排除标准
- •Prior treatment of non-small cell carcinoma with PDT or with APC in the last 3 months.
- •Subjects with tracheal lesions or carinal lesions that compromise both main stem bronchi.
- •Subjects who have undergone pneumonectomy.
- •Tumor involving or eroding into major blood vessels.
- •Presence of a tracheoesophageal or bronchoesophageal fistula.
- •Subjects receiving concurrent external beam radiation therapy.
- •Radiation therapy within the previous two weeks.
- •Inability to adhere to sunlight precautions.
- •Severe hepatic impairment.
- •Severe renal impairment.
- •Porphyria or hypersensitivity to porphyrins.
- •Subjects requiring supplemental O2 with a flow of greater than 3 lpm to keep resting oxygen saturations greater than 90%.
- •History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
- •Prisoners or subjects who are involuntarily incarcerated.
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- •Subjects demonstrating an inability to comply with the study and/or follow-up procedures.
- •Females who are pregnant.
- •Individuals who cannot provide consent themselves.
结局指标
主要结局
Treatment time until failure
时间窗: 90 days
Measure the time until treatment failure. Treatment failure is defined in this study as the occurrence of any of the following: failure to improve airway patency, airway-re-obstruction, need for additional airway intervention, and/or worsening symptoms at 90 days after the last PDT or APC treatment .
次要结局
- Median survival time(6 months)
- Percent reduction in airway obstruction as measured by bronchoscopy at 30 and 90 days after the last PDT or APC treatment(30 days through 90 days)
- Change in dyspnea (as measured by the transitional dyspnea index (TDI), using the score obtained from the Baseline Dyspnea Index (BDI) as the baseline comparator) at 30, 60, 90, and 180 days after the last PDT or APC treatment(30 days through 180 days)
- Change in mean score of quality of life using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer Module (EORTC QLQ-LC13) at 30, 90 and 180 days after the last PDT or APC(30 days through 180 days)
- Need for additional bronchoscopic therapies for either endobronchial obstruction at the treated site or for recurrent obstruction with no additional therapies offered at 30, 90, and 180 days following the last PDT or APC treatment(30 days through 180 days)
- Resolution of atelectasis, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment(30 days through 180 days)
- Change in cough, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment using categorical measures (worsened, unchanged, improved, resolved)(30 days through 180 days)
- Proportion of patients experiencing treatment failure at 90 days(90 days)
- Resolution of post-obstructive pneumonia, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment(30 days through 180 days)
- Change in hemoptysis, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment using categorical measures (worsened, unchanged, improved, resolved)(30 days through 180 days)
- Change in Karnofsky performance status, if present, at 30, 60, 90, and 180 days after the last PDT or APC treatment using categorical measures (worsened, unchanged, improved, resolved).(30 days through 180 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic DermatitisSeborrheic DermatitisNCT03114111University of California, Davis12
已完成
不适用
A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis SuppurativaHidradenitis SuppurativaNCT00395187University of Kansas15
进行中（未招募）
3 期
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).Superficial Basal Cell CarcinomaNCT03573401Biofrontera Inc.187
撤回
2 期
Photodynamic Therapy in the Treatment of Malignant Intracranial TumorsMalignant Intracranial TumorsAnaplastic AstrocytomasAnaplastic OligodendrogliomasAnaplastic EpendymomaGlioblastoma MultiformeNCT00243490National Taiwan University Hospital5
已完成
2 期
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in AdultsAcne VulgarisNCT05080764Biofrontera Inc.120